AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Warnings and Precautions:
Bleeding is the most commonly reported adverse reaction.
For additional information, refer to the full Prescribing Information.
This website is intended for United States healthcare professionals only.
Aggrastat, registered trademark of Medicure International, Inc. Copyright © 2018 Medicure Incorporated. All rights reserved.